Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer

NCT ID: NCT02090101

Last Updated: 2023-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-10
• Study Completion Date: 2017-05-15

Brief Summary

The metastatic colon cancer is a major public health problem despite advances in chemotherapy; few new drugs are in development for the treatment of this pathology.

Many studies have shown that human colon cancer is a tumor that is recognized by the immune system and the presence of lymphocytic infiltrates in the tumor bed is associated with a better prognosis. Conversely, the effect of chemotherapy on the immune response is little studied.

Recently the importance of myeloid suppressor cells (MDSC) in the development of colon cancer and the effect of 5- fluorouracil on this cell population has been highlighted. An accumulation of these cells in the blood and lymphoid organs during tumor progression is observed. Moreover, it has been established that the death of MDSC induced by 5-fluorouracil induces activation of caspase -1 and IL-1beta by these MDSC.

These events promote the polarization of CD4 T cells in intratumoral Th17 lymphocytes. The IL- 17 produced by these cells exerts a pro-angiogenic effect in inducing proliferation of endothelial cells expressing and thus limits the effect of 5- fluorouracil endoglin.

In humans, it has also been observed that chemotherapy using 5- fluorouracil and in particular LV5FU2 association +/- bevacizumab induces rapid death of blood MDSC as well as activation of caspase 1 in these cells. Thus, production of IL - 1 is detected in the serum of patients after 24 hours of the administration of 5-fluorouracil.

Chronic inflammation and the production of interleukin- 1 can alter the effectiveness of anti -tumor immune responses and facilitate angiogenesis. Many preclinical data suggest a role of anti -tumor inhibition of IL- 1beta, but the effect of a combination of chemotherapy and an inhibitor of IL - 1beta has not yet been tested in human.

Anakinra is a drug used in humans for many years to treat signs and symptoms of rheumatoid arthritis. In combination with methotrexate, in patients whose response to methotrexate alone is not satisfactory it had shown interesting results. The dose used clinically is 100 mg per day which is the dose that is proposed to be tested in this study.

In this context it should be remembered that methotrexate is a chemotherapeutic agent from the class of antimetabolites such as 5- fluorouracil.

RCP of this drug indicate that in studies originator toxicity was similar between the control arm and anakinra arm with an increase in serious infections (1.8 % vs 0.7 %) and an increased incidence of neutropenia (2.5 % neutropenia > grade = 1). The main toxicity observed is a painful inflammatory reaction at the injection site in 70 % of patients The investigators believe that this project could permit to validate in man preclinical observations showing an anti-tumor potential for combination anakinra and 5 fluorouracil.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ANAKINRA

LV5FU2 + bevacizumab + anakinra

Group Type: EXPERIMENTAL

ANAKINRA

Intervention Type: DRUG

Interventions

ANAKINRA

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Man or woman
• Age ≥ 18 and ≤ 80 years
• Performance status of 0 or 1 according to the ECOG score of WHO
• Patient with Metastatic colorectal non-curative and progression on therapy in first -line therapy containing 5-fluorouracil and bevacizumab cancer.
• Patient with low or intermediate risk defined by modified Kohne's criteria
• Hepatic metastases ≥ 1 cm
• Evaluation Review (CT chest, abdomen and pelvis ) made in the previous 4 weeks and showing the presence of a measurable lesion according to RECIST 1.1 criteria.
• Indication treatment LV5FU2 + bevacizumab validated
• Patient whose understanding of the study is good
• Biological values within the following limits :

• Bilirubin ≤ 1.5 x upper limit of normal ( N)
• AST and ALT ≤ 5 N
• Creatinin ≤ 1.5 N and creatinin clearance > 60 ml / min
• Neutrophils ≥ 1.5 . 109 / L
• Platelets ≥ 100 . 109 / L
• Hemoglobin ≥ 9 g / dL ( even if includable patients were transfused ) .
• Albumin ≥ 30 g / L
• Serological hepatitis B , C and HIV negative
• Information given and signed informed consent
• Patient affiliated to a social security system
• For women of childbearing age , the need for effective contraception.

Exclusion Criteria

Related to the disease:

• Other cancer within 5 years prior to entry into the trial or concomitant (except carcinoma in situ of the cervix or basal cell carcinoma of the skin ) .
• Presence of brain metastasis
• Prognosis estimated survival <3 months

Related to treatment :

• Presence of a contraindication to bevacizumab ( major surgery in the previous 28 days , the risk of arterial thrombosis, risk of bleeding , deep vein thrombosis without effective anti- coagulant treatment or unbalanced anticoagulant treatment) Concomitant systemic
• Immunotherapy , immunosuppressants, corticosteroids ≥ 1mg/kg or hormone therapy : corticosteroids administered chronically , immunosuppressive therapy, biotherapy administered under the management of inflammatory disease (anti -TNF , anti- IL6 ... )
• Hypersensitivity to one of the compounds of treatments
• Latex Hypersensitivity ( the cap of the syringe containing anakinra contains dry natural rubber, a derivative of latex), which may cause allergic reactions
• Peripheral neuropathy grade ≥ 2
• History of autoimmune disease or inflammatory

Related to patient conditions :

• Participation during or within 30 days prior to study entry to another clinical trial with an experimental molecule.
• Serious disease unbalanced, underlying infection that may prevent the patient from receiving treatment
• Intestinal occlusion or sub- occlusion or history of inflammatory bowel disease
• Pregnancy (test mandatory inclusion pregnancy) , lactation or lack of effective contraception for men and women of childbearing age
• Psychiatric disease compromising understanding of the information or the accomplishment of the study
• Patient under guardianship, curatorship or judicial protection
• Unable to sign the informed consent or to submit to medical follow-up for geographical, social or psychological reasons.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Georges Francois Leclerc

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Centre Georges François Leclerc

Dijon, Burgundy, France

Countries

France

Other Identifiers

2013-003367-55

Identifier Type: -

Identifier Source: org_study_id